General Principles: The purpose of this guideline is to assist the primary care practitioner in detecting, diagnosing, and adequately treating clinical depression in patients 18 years of age and older. Depression is extremely common in primary care medicine. It is thought to be more prevalent than hypertension (6-17% compared to 5.8%). The WHO considers depression to be a major cause of disability worldwide.

Nearly three quarters of depressed patients will at some point present to their primary care practitioner, often with somatic complaints, but only 50% of these cases are diagnosed. Primary Care Providers should be skilled at evaluating and diagnosing this common disorder.

Clinical depression is a highly treatable illness. A fair to full response to therapy can be expected in 66% to 80% of patients with major depression. Unfortunately, of those diagnosed, only 10% get adequate treatment.

The “costs” of depression extend beyond absenteeism, loss of productivity and include unnecessary suffering for patients and their families, and suicide.

Disease Definition: Clinical depression encompasses four DSM-V diagnoses of unipolar affective disorders - Major Depression, Persistent Depressive Disorder (Dysthymia), Premenstrual Dysphoric Disorder, and Other Depressive Disorders.

A. Major Depression: A major depressive episode can be characterized by a period of at least 2 weeks in which five or more of the following symptoms have been present and represent a change from prior functioning. At least one of the symptoms must be either depressed mood or loss of interest or pleasure in nearly all activities (anhedonia).

- Depressed mood most of the day, nearly every day, as self-reported or observed by others
- Diminished interest or pleasure in all or almost all activities most of the day, nearly every day
- Significant weight loss when not dieting, weight gain, or decrease or increase in appetite nearly every day
- Insomnia or hypersomnia nearly every day
- Psychomotor agitation or retardation nearly every day
- Fatigue or loss of energy nearly every day
- Feelings of worthlessness or excessive or inappropriate guilt nearly every day
- Diminished ability to think or concentrate nearly every day
- Recurrent thoughts of death, recurrent suicidal ideation without a specific plan
Depression can be characterized as mild (few symptoms, minor functional impairment), moderate, or severe (many more symptoms than required for diagnosis with significant functional impairment).

Seasonal affective disorder is a subtype of major depression with seasonal onset and remission.

B. **Persistent Depressive Disorder:** Depressed mood for most of the day, for more days than not for at least two consecutive years without a period of greater than two months of absence of symptoms. In addition, at least two of the following must be present:

- Poor appetite or overeating
- Insomnia or hypersomnia
- Low energy or fatigue
- Low self-esteem
- Poor concentration or difficulty making decisions
- Feelings of hopelessness

C. **Premenstrual Dysphoric Disorder**—Mood disorder present in most menstrual cycles in the prior year associated with significant distress and impairment of functioning. Symptoms must be present during the week prior to menses and resolve within a few days of onset of the menstrual period.

One or more of the following must be present:

- Mood swings, sudden sadness, increased sensitivity to rejection
- Anger or irritability
- Hopelessness, depressed mood, self-critical thought
- Tension, anxiety, feeling on edge

One or more of the following symptoms must also be present (to total five when combined with symptoms above):

- Difficulty concentrating
- Change in appetite, overeating, food craving
- Diminished interest in usual activities
- Low energy, fatigue
- Feeling overwhelmed or out of control
- Insomnia or hypersomnia
- Breast tenderness, weight gain, bloating, joint or muscle aches

**Other Depressive Disorders:** This category encompasses depressive disorders related to substance abuse, medication side effects, medical conditions or other specified or unspecified reasons.

**Disease Detection and Screening:**

A. **Screening:** The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. Detection of depression can be enhanced by the use of a screening tool such as a questionnaire that identifies patients who are at risk of depression. The Patient Health Questionnaire- 2 and 9 (PHQ-2, PHQ-9) are two item and nine item tools, respectively, for assisting primary care clinicians in diagnosing depression as well as selecting and monitoring treatment. Screening tools for special populations (Edinburgh Postnatal Depression Scale for pregnant and postpartum women). **Initial Approval Date and Reviews:** April 2013, April 2015, April 2017

**Most Recent Revision and Approval Date:**

**April 2017**

© Copyright MedStar Health, 2012

**Next Scheduled Review Date:** April 2019 Ambulatory Best Practice
pregnant and postpartum patients and Geriatric Depression Scale for elderly patients) also exist but are not clearly preferable to the PHQ-9. In general, sensitivity of the various screening tools is 80-90% and specificity is 70-85%. Patients who screen positive should be further evaluated to confirm the diagnosis, evaluate for other causes, and assess the presence of co-existing psychiatric illness. (Tools attached end of guideline)

B. High Risk Groups:
1. The primary risk factors for depression are the following:
   - Prior episodes of depression
   - Prior suicide attempts
   - Family history of depressions
   - Female gender
   - Age of onset under 40
   - Postpartum period
   - Medical co-morbidity
   - Lack of social support
   - Stressful life events
   - Current alcohol or substance abuse

2. Patients with the following chronic medical illnesses are at significantly higher risk for chronic depression. It has been shown that undetected depression in these groups can worsen the course of their medical illness.
   a) Stroke - Subgroups of post-CVA patients have depression that appears to be causally related to the injury, especially if the insult is located in the left basal ganglia or left dorsal lateral frontal cortex.
   b) Dementia - Depression is often seen in patients with or antecedent to primary dementia. Thirty to forty percent of Alzheimer’s disease patients demonstrate depressive mood symptoms sometime during their illness.
   c) Diabetes - Major depressive syndrome is three times more common in this population.
   d) Coronary Artery Disease - The prevalence of various forms of depression is estimated at 40 - 65%.
   e) Cancer - Major depression occurs in approximately 25% of this population
   f) Fibromyalgia
   g) HIV/AIDS

C. Differential Diagnosis:
1. Psychiatric: Differentiation from other psychiatric and substance use disorders can be difficult. Consider:
   • Bipolar disorder – if there have been features of mania/hypomania. Note that SSRI’s may trigger manic episodes in patients with bipolar disorder.
   • Alcohol dependence/drug dependence – organic depression often accompanies substance abuse and resolves in 4-8 week of abstinence
   • Personality disorders

2. Bereavement: Distinguishing normal grief from depression can be challenging, since the response to death of a loved one varies between individuals and has a significant cultural overlay. Features favoring grief rather than major depression include the following:
   • Waves or pangs of grief or sadness rather than pervasive depressed mood
   • Preservation of self-esteem
   • Hope that the future will be better rather than a sense of hopelessness

3. Medical: A variety of medical conditions and medications can cause a depressive-like syndrome. These causes should be treated first. If the syndrome persists, a diagnosis of clinical depression can be made
and treated accordingly. Medical conditions may include: hypothyroidism, Addison’s disease, vitamin B12 deficiency, parathyroid conditions, brain tumors, cocaine withdrawal, amphetamine withdrawal, etc.

D. Assessing the Patient for Suicide Potential
All depressed patients should have an initial evaluation for suicide potential. Risk factors for suicide include:

- male sex
- family history of suicide
- psychotic symptoms
- hopelessness
- general medical illnesses
- living alone with little social support
- prior suicide attempts.
- Borderline personality disorder

Questions about plans and means should be asked. If the evaluation reveals any degree of suicidal risk, an immediate call should be made for a psychiatric assessment.

**MEDICATIONS REPORTEDLY ASSOCIATED WITH DEPRESSION**

<table>
<thead>
<tr>
<th>Cardiovascular Drugs</th>
<th>Hormones</th>
<th>CNS Active</th>
<th>Anti-cancer Agents</th>
<th>Anti-inflammatory</th>
<th>GI Drugs</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-methyldopa</td>
<td>Oral Contraceptives</td>
<td>Benzodiazepines</td>
<td>Cycloserine</td>
<td>NSAIDS</td>
<td>Ranitidine</td>
<td>Alpha &amp; Beta Interferons</td>
</tr>
<tr>
<td>Reserpine</td>
<td>Glucocorticoids</td>
<td>Neuroleptics</td>
<td>Tamoxifen</td>
<td>Ethambutol</td>
<td>Cimetidine</td>
<td>Varenicline</td>
</tr>
<tr>
<td>Guanethidine</td>
<td>Anabolic steroids</td>
<td>L-Dopa</td>
<td>GnRH agonists</td>
<td>Disulfiram</td>
<td>Metoclopramide</td>
<td>Isotretinoin</td>
</tr>
<tr>
<td>Clonidine</td>
<td></td>
<td>Baclofen</td>
<td></td>
<td>Sulfonamides</td>
<td></td>
<td>Efavirenz</td>
</tr>
<tr>
<td>Thiazides</td>
<td></td>
<td>Triptans</td>
<td></td>
<td>INH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digitalis</td>
<td></td>
<td>Arpiprazole</td>
<td></td>
<td>Dapsone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta blockers</td>
<td></td>
<td>Quetiapine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Clinical Management:**

**A. Goals**
1. Reduce, if not remove, all signs and symptoms of the disease.
2. Restore occupational and psychosocial functioning
3. Reduce the likelihood of relapse and recurrence.

**B. Types of Treatment:**

**Initial Approval Date and Reviews:**
April 2013, April 2015, April 2017

**Most Recent Revision and Approval Date:**
April 2017

**Next Scheduled Review Date:**
April 2019 Ambulatory Best Practice
1. Medication - Patients with moderate to severe clinical depression are appropriate candidates to be treated with medication, whether or not formal psychotherapy is also used.

2. Psychotherapy - Patients with mild to moderate clinical depression (usually dysthymia or depressive disorder NOS) may be managed with psychotherapy alone, if the patient prefers. If symptoms do not improve within 2-3 months, then medication should be strongly considered.

3. Medication and psychotherapy - This may be advantageous for complicated, chronic depressions and for patients with only a partial response to either treatment alone.

4. Electroconvulsive therapy (ECT) - This is only for certain patients after psychiatric consultation.

C. Medication Selection and Management (see table, page 5)

1. Selective Serotonin Re-uptake Inhibitors (SSRI) should be the first choice unless the patient has a history or risk of intolerable side effects, is taking other medications that put them at risk for drug interaction, or has a personal or family history of a positive response to another class of anti-depressants.

2. Advantages to using SSRI’s include: ease of dosing, lack of histaminic, muscarinic and adrenergic antagonism, the potential for co-treating other psychiatric conditions (e.g. panic disorder, ADHD, bulimia, obsessive-compulsive disorder, alcoholism, self-injurious behaviors and premenstrual syndrome), and effectiveness for treating concurrent medical conditions (e.g. headaches, chronic pain, Raynaud’s and some sexual disorders). Limitations of all SSRI’s can include agitation, akathisia, nausea, diarrhea, Serotonin syndrome, Parkinson like tremor and possible sexual side effects.

3. Early signs of positive clinical response can occasionally be seen as early as one week into therapy but usually 4-6 weeks is required. Adequate treatment for 6-8 weeks is necessary before concluding a patient is not responding to a particular medication. If side effects are tolerable, then titration of the dosage upward is a first adjustment strategy to consider. Occasionally, titration of the dosage downward is a first adjustment strategy if it is concluded that the depressive symptoms are responding but side effects are interfering. If a patient is deemed unresponsive to a particular SSRI or has intolerable side effects, then a trial of a different SSRI yields positive results for about 50% of the patients. Switching from an SSRI to a tricyclic antidepressant in this situation has a 62% response rate. Thus, the data suggest that either a switch within the class or a switch to a new class is an acceptable strategy.

4. Additional medication options include combining anti-depressants or adding augmentation medications. Combining anti-depressants and adding augmentation medications is best managed by a psychiatrist.

D. Expectations of Treatment: Active treatment should yield a response. As noted above, a response may be evident in as little as a week or treatment may need to be continued for as long as 8 weeks before it is deemed a failure and an alternate strategy adopted. Remission, or full response to treatment, may take longer. Response and remission are not the same. No matter what the treatment modality that induced the response, it should be continued to keep the patient in remission, i.e., prevent relapse. Only after the patient has been in full remission for 4-6 months should an attempt to taper the dosage of medication be entertained. Relapse is common and close follow up will be needed. Approximately 50% of patients will go on to have a relapse. Given a second episode of depression, the relapse rate is 70%, with a 3rd episode, it is >80% and after a 4th episode, it is >90%. For patients with a history of recurrent disease, prolonged, or even lifelong therapy, may be needed. And even long term medication is not fool proof; relapses have been
reported.

If the decision is made to try to discontinue the selected medication, it should be tapered to prevent withdrawal symptoms. Patients, and their families, should be warned about early signs of recurrence of the depression.

Patients should be seen 2-4 weeks after starting therapy to assess medication tolerability, suicide risk and early response. There should be 3 contacts within the first 12 weeks. Patients on stable, long-term medication should be seen in the office every 3-6 months for re-evaluation of the treatment plan and efficacy.

E. **Continuation of Treatment:** If this is a first episode of clinical depression in a patient with a good premorbid mood history and without a significant family history of depression, then effective medication should be continued at least for 6-12 months before considering discontinuation. Some patients are candidates for indefinite medication maintenance. These patients should be re-evaluated every 3-6 months. If medicines are tapered or discontinued, patients should be warned about early signs of recurrence.

F. **Psychiatric Referral:** Referral for mental health consultation, treatment and/or psychotherapy can occur at any time at the PCP’s discretion and/or the patient’s choice.

Immediate referral is recommended for:
- **significant evidence of danger to self and/or others**
- **presence of psychotic symptoms**

Referral is strongly recommended for:
- **depression with co-morbid psychiatric or substance abuse disorders**
- **suspicions of bipolar disorder**
- **depression during pregnancy and the postpartum**
- **treatment-resistant depression**
- **childhood depression**
- **depression with dementia**

**Patient Education:**

A. **Clinician counseling:**

1. **Natural history of the disease:** Depression isn’t just a brief blue mood or a passing sadness that lifts in a few hours or even a few days. Clinical Depression occurs when a person experiences physiological symptoms such as changes in sleep, appetite, sexual function, feeling of sadness and difficulty in the ability to function normally. These symptoms last for several weeks or more.

2. **Treatment Plan:**
   - **Medication** - Patients with moderate to severe clinical depression are appropriate candidates for medication. Compliance with antidepressants can be a problem. Discuss with patients that usually 4-6 weeks of medication is required for a full response. Explain and discuss common side effects of medications such as sexual dysfunction, restlessness, anticholinergic effects, orthostatic hypotension, and GI symptoms. Medication guides regarding the risk of suicidal thoughts and actions with antidepressants will be provided by the pharmacy when medications are dispensed.
   - **Psychotherapy** - Can be successful for patients with mild to moderated clinical depression. If symptoms do not significantly improve within 2-3 months then medication should be considered.
   - **Medication and Psychotherapy** - This combination can be beneficial for complicated, chronic
depression or with individuals who have experienced only partial response to either treatment alone.

3. Self help strategies:
   • Identify activities that make you feel better and try to focus on them. Do things for yourself. Take up hobbies. Listen to music. Participate in activities even when you may not want to.
   • Do not withdraw from others. Join a support group and talk to your friends. Call on your support group or therapist for help when you need it. Ask for assistance at home and work if the load is too great to handle.
   • Eat nutritious, well-balance meals. Avoid drinking alcohol and coffee.
   • Exercise on a regular basis, several times a week
   • Get adequate rest and keep your sleep cycle as regular as possible.
   • Concentrate on good grooming and cleanliness.
   • Perform progressive relaxation exercises daily and diaphragmatic breathing exercises during times of high stress.
   • Perform frequent mental imaging of good life experiences. Develop and maintain an attitude that things will work out.
   • Learn new, positive problem-solving techniques.
   • Call your provider or therapist if you feel suicidal.

B. Resources:
   • National Institute Mental Health: 866-615-6464 or http://www.nimh.nih.gov/health/publications/index.shtml
   • Center for Disease Control: https://www.cdc.gov/mentalhealth/gen-resources.htm
   • Suicide Prevention Hotline: 1-800-273-TALK or 1-800-273-8255
   • American Psychiatric Association: http://www.psychiatry.org/mental-health
   • Mental Health America: http://www.nmha.org/mental-health-information

---

Initial Approval Date and Reviews:
April 2013, April 2015, April 2017

Most Recent Revision and Approval Date:
April 2017

Next Scheduled Review Date:
April 2019 Ambulatory Best Practice

© Copyright MedStar Health, 2012
## Selected Formulary for Medical Management of Depression

### I. Selective Serotonin Reuptake Inhibitors (SSRI’s)

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Initial Dose *</th>
<th>Dosing Range *</th>
<th>Positives</th>
<th>Limitations</th>
</tr>
</thead>
</table>
| citalopram *Celexa®* | 20mg daily | 20-40mg daily max dose 20 mg for age >60 | • Minimal drug interactions compared with other SSRIs  
• Generic available  
• Lower incidence of sexual dysfunction | Do not use doses >40 mg due to risk of QT prolongation |
| escitalopram *Lexapro®* | 10mg daily | 10-20mg daily | • Minimal drug interactions compared with other SSRIs  
• Possible quicker onset in resolving panic-related | |
| fluoxetine *Prozac®* | 10-20mg daily (Elderly dose 10mg/day) | 20-80mg daily | • Energizing feeling  
• Lower cost of care | • Longer ½ life  
• More agitation |
| paroxetine *Paxil®* | 10-20mg daily (Elderly dose 10mg/day)  
paroxetine *Paxil® CR* | 25 mg daily | 20-50mg daily Maximum dose 40 mg in the elderly | • Better for agitation  
• Usually has better pricing | • More problems with withdrawal  
• More anticholinergic side effects |
| sertraline *Zoloft®* | 25-50mg daily | 25-200mg daily | More helpful in Parkinson’s patients | Usually needs higher doses to be effective  
• More titration |
| vilazodone *Viibryd®* | 10 mg daily | 40 mg daily target dose | May have low sexual side effects  
• May lead to less weight gain | |

---

**Initial Approval Date and Reviews:**  
April 2013, April 2015, April 2017

**Most Recent Revision and Approval Date:**  
**April 2017**

**Next Scheduled Review Date:**  
April 2019 Ambulatory Best Practice

© Copyright MedStar Health, 2012
<table>
<thead>
<tr>
<th>Drug name</th>
<th>Initial Dose*</th>
<th>Dosing Range *</th>
<th>Positives</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>bupropion</td>
<td>100mg bid</td>
<td>200-450mg daily in 3-4 divided doses Max single dose=150mg tid Max 400mg in divided doses Max 450mg daily as single dose</td>
<td>• Low sexual side effects • May help with nicotine addiction • Increases total REM time • Effective in many SSRI non-responders</td>
<td>• Seizures 0.4% (dose dependent, more common with immediate release) • GI upset • Tinnitus • Agitation • Tremor</td>
</tr>
<tr>
<td>Wellbutrin®</td>
<td>150mg qam</td>
<td>•</td>
<td>•</td>
<td></td>
</tr>
<tr>
<td>Wellbutrin SR®</td>
<td>150 mg qam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wellbutrin XL®</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Potential side effects of all SSRI’s include:** agitation, nausea, diarrhea, sexual side effects, akathisia and serotonin syndrome (hyperthermia, rigidity, myoclonus, autonomic instability, and potentially delirium and coma).

**II. Norepinephrine Dopamine Reuptake Inhibitors (NDRI’s)**

**III. Serotonin Norepinephrine Reuptake Inhibitors (SNRI’s)**

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Initial Dose*</th>
<th>Dosing Range *</th>
<th>Positives</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>duloxetine</td>
<td>20mg bid</td>
<td>20-30mg bid or 60mg once daily Max 60mg/day</td>
<td>• Benefit in neuropathic pain and depression</td>
<td>• Possible urinary retention and hepatotoxicity • Possible elevation in BP • Use not recommended in patients with renal insufficiency (creatinine clearance&lt;30) or end stage renal disease • Use not recommended in patients with hepatic disease given potential for contributing to hepatic failure</td>
</tr>
<tr>
<td>Drug name</td>
<td>Initial Dose</td>
<td>Dosing Range</td>
<td>Positives</td>
<td>Limitations</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>-----------------------------------------------</td>
<td>--------------------------------------</td>
</tr>
</tbody>
</table>
| venlafaxine Effexor®   | 75mg daily in divided doses | 150-375mg daily (w/food) | • Possible greater efficacy  
• Low side effects  
• Possible greater efficacy w/chronic pain | • BP elevation  
• Weight gain  
• Frequent dosing  
• Sexual side effects |
| Effexor XR®            | 37.5-75mg daily | 225mg daily (w/food) |  |  |
| desvenlafaxine Pristiq® | 50 mg daily | 50 mg daily | • Once daily administration | • Doses of 50-400 mg daily have been studied; no additional benefit has been observed at doses > 50 mg  
• Possible BP elevation  
• Nausea/dizziness  
• Similar side effect profile to venlafaxine |
| levomilnacipran Fetzima® | 20 mg daily x 2 day then 40 mg daily | 120 mg daily | May be more beneficial for tx of sx related to norepinephrine deficiency (decreased concentration, mental and physical slowing, decreased self care) |  |

Potential side effects of all SNRI’s include; agitation, nausea, diarrhea, sexual side effects, akathisia and serotonin syndrome (hyperthermia, rigidity, myoclonus, autonomic instability, and potentially delirium and coma).

IV. Serotonin Antagonist and Reuptake Inhibitors

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Initial Dose</th>
<th>Dosing Range</th>
<th>Positives</th>
<th>Limitations</th>
</tr>
</thead>
</table>
| trazodone Desyrel® | 50mg tid (Depression) | 150-400mg daily in divided doses (w/food) | • Sedative properties | • Over-sedation and/or possible orthostasis  
• Priapism |
|           | 25-50mg hs (Insomnia) | Insomnia: 50-100mg hs (some may require antidepressant) |  |  |
### V. Tetracyclic Antidepressants

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Initial Dose*</th>
<th>Dosing Range*</th>
<th>Positives</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mirtazapine</td>
<td>15mg daily hs</td>
<td>15-45mg hs</td>
<td>• Appetite stimulation</td>
<td>• Oversedation</td>
</tr>
<tr>
<td>Remeron®</td>
<td></td>
<td></td>
<td>• Sedative properties</td>
<td>• Weight gain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Well known therapeutic and toxic levels</td>
<td>• Metabolic disorders</td>
</tr>
</tbody>
</table>

### VI. Tricyclic Antidepressants (TCA’s)

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Initial Dose*</th>
<th>Dosing Range *</th>
<th>Positives</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amitriptyline</td>
<td>25-75mg hs</td>
<td>75-300mg daily</td>
<td>• Sedative properties</td>
<td>• Weight gain</td>
</tr>
<tr>
<td>Elavil®</td>
<td>(Elderly dose 10mg/d)</td>
<td></td>
<td>• Efficacy in neuropathic pain</td>
<td>• Cardiac arrhythmia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Well known therapeutic and toxic levels</td>
<td>• Orthostatic hypotension</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Less anticholinergic</td>
<td>• Anticholinergic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Not recommended for elderly</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>25-50mg hs</td>
<td>150 mg/day as single or divided doses</td>
<td>Well known therapeutic and toxic levels</td>
<td>Cardiac arrhythmias</td>
</tr>
<tr>
<td>Pamelor®</td>
<td></td>
<td></td>
<td>• Less anticholinergic</td>
<td></td>
</tr>
<tr>
<td>Amoxapine</td>
<td>50-150mg daily</td>
<td>100-400mg daily</td>
<td>• Potential benefit in depression with psychosis</td>
<td>EPS or tardive dyskinesia (avoid in Parkinson’s)</td>
</tr>
<tr>
<td>Aserpin®</td>
<td></td>
<td>Doses &gt;300mg/day should be divided Max dose 300mg in older adults</td>
<td></td>
<td>Sedation</td>
</tr>
<tr>
<td>Desipramine</td>
<td>25-50mg daily</td>
<td>100-200mg daily Max 300mg/day</td>
<td>Sedative properties</td>
<td>Weight gain</td>
</tr>
<tr>
<td>Norpramin®</td>
<td></td>
<td></td>
<td>• Cardiac complications</td>
<td></td>
</tr>
<tr>
<td>Drug Name</td>
<td>Initial Dose</td>
<td>Dosing Range</td>
<td>Positives</td>
<td>Limitations</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>-----------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>doxepin <em>Sinequan®</em></td>
<td>25-50mg daily</td>
<td>75-150mg daily</td>
<td>• Sedative properties</td>
<td>• Oversedation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Patients with neurodermatitis</td>
<td>• Weight gain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Patients with cardiac complications</td>
<td>• Cardiac complications</td>
</tr>
<tr>
<td>imipramine <em>Tofranil®, Tofranil PM</em></td>
<td>25mg hs 50-150mg</td>
<td>Once daily or in divided doses</td>
<td>• Minimal drug interactions</td>
<td>• Contraindicated in post MI patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Patients with insomnia</td>
<td>• Dose 30-100mg/day recommended in elderly and peds</td>
</tr>
<tr>
<td>protriptyline <em>Vivactil®</em></td>
<td>15mg tid 15-60mg tid-qid</td>
<td></td>
<td>• Good for withdrawn or anergic patients</td>
<td>• Multiple daily dosing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Patients with insomnia or anxiety</td>
<td>• Cardiac complications</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Weight gain</td>
<td>• Weight gain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Sedation</td>
<td></td>
</tr>
<tr>
<td>trimipramine <em>Surmontil®</em></td>
<td>25mg hs 50-150mg hs</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**VII. Monoamine Oxidase Inhibitors (MAOIs)**

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Initial Dose</th>
<th>Dosing Range</th>
<th>Positives</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>isocarboxazid <em>Marplan®</em></td>
<td>10mg bid 40-60mg/day divided bid-qid</td>
<td>• Patients with resistant or atypical depression or anxiety</td>
<td>• Dietary restrictions</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Drug interactions</td>
<td>• Avoid in patients with HTN or cardiac conditions</td>
</tr>
<tr>
<td>phenelzine <em>Nardil®</em></td>
<td>15mg tid 60-90mg/day divided tid</td>
<td>• As above</td>
<td>• As above</td>
<td></td>
</tr>
<tr>
<td>selegiline transdermal patch <em>Emsam®</em></td>
<td>6mg/24 hours 6-12mg/24 hours</td>
<td>• As above</td>
<td>• Less weight gain</td>
<td>Caution in Parkinson’s</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Less sexual</td>
<td>• As above</td>
</tr>
<tr>
<td>tranelypromine <em>Parnate®</em></td>
<td>30mg daily in divided doses 30-60 mg/day in divided doses</td>
<td>• As above</td>
<td>• As above</td>
<td></td>
</tr>
</tbody>
</table>

**References**

9. DeJesus, Ramona S. et al. A System-Based Approach to Depression Management in Primary Care Using the Patient Health Questionnaire-9
Clinical Depression Algorithm

- Diagnosis of Clinical Depression is made

  - Referral to Mental Health Services (LCSW, Clinical Psychologist, or Psychiatrist) at anytime patient requests or has symptoms

    - If partial or complete remission
      - Continue treatment at same or adjusted dosage and re-evaluate periodically for side effects and continued positive response

      - If candidate for medication discontinuation at 6-12 months, D/C medication gradually and advise patient and family of early signs of recurrence

      - If candidate for indefinite antidepressant maintenance, continue antidepressant and re-evaluate every 3-6 months

    - Re-evaluate periodically during first 6-8 weeks for side effects, positive response and dosage adjustments

      - If unsatisfactory or no response
        - Refer to Mental Health Services or switch antidepressants and repeat prior step

Primary Care Physician initiates treatment with an antidepressant, psychotherapy or both
Geriatric Depression Scale

Name ____________________________ PCP ____________________________
DOB ____________________________ Date Completed __________________

Circle your answer of YES or NO for each of the following items, do not skip any items.

1. Are you basically satisfied with your life YES NO
2. Have you dropped many of your activities and interests? YES NO
3. Do you feel that your life is empty? YES NO
4. Do you often get bored? YES NO
5. Are you in good spirits most of the time? YES NO
6. Are you afraid that something bad is going to happen to you? YES NO
7. Do you feel happy most of the time? YES NO
8. Do you often get restless and fidgety? YES NO
9. Do you prefer to stay at home, rather than going out and doing new things? YES NO
10. Do you feel you have more problems with memory than most? YES NO
11. Do you think it is wonderful to be alive now? YES NO
12. Do you feel pretty worthless the way you are now? YES NO
13. Do you feel full of energy? YES NO
14. Do you feel that your situation is hopeless? YES NO
15. Do you think that most people are better off then you are? YES NO

Cut point for positive response: ≥ 6
Time to administer: 2-5 minutes
Can be used to monitor treatment response
**Patient Health Questionnaire--2**

Name_________________________________________ DOB________________________

Date Completed______________________________

Over the past two weeks, how often have you been bothered by any of the following problems?

<table>
<thead>
<tr>
<th></th>
<th>Not at all</th>
<th>Several days</th>
<th>More than half the days</th>
<th>Nearly every day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Little interest or pleasure in doing things.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Feeling down, depressed, or hopeless.</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

Total point score: ______________

These questions, which can be used by practitioners as part of a general medical review of systems, can help identify which patients are exhibiting signs and symptoms of depression, and which of them may benefit from completing the PHQ-9. It can be administered by asking for responses as yes/no or rated on a scale of zero to three. Any “yes” or a score of three or more indicates possible depression and requires further evaluation.

**Score interpretation: Cut point for positive response ≥ 3**

<table>
<thead>
<tr>
<th>PHQ-2 score</th>
<th>Probability of major depressive disorder (%)</th>
<th>Probability of any depressive disorder (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>15.4</td>
<td>36.9</td>
</tr>
<tr>
<td>2</td>
<td>21.1</td>
<td>48.3</td>
</tr>
<tr>
<td>3</td>
<td>38.4</td>
<td>75.0</td>
</tr>
<tr>
<td>4</td>
<td>45.5</td>
<td>81.2</td>
</tr>
<tr>
<td>5</td>
<td>56.4</td>
<td>84.6</td>
</tr>
<tr>
<td>6</td>
<td>78.6</td>
<td>92.9</td>
</tr>
</tbody>
</table>

Patient Health Questionnaire--9

Patient's name: ___________________________ Date: ____________

Over the past two weeks, how often have you been bothered by any of the following problems? (For each question, circle the number that represents the best answer.)

<table>
<thead>
<tr>
<th>Question</th>
<th>Not at all</th>
<th>Several days</th>
<th>More than one half of the days</th>
<th>Nearly every day</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Little interest or pleasure in doing things</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>2. Feeling down, depressed, or hopeless</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>3. Trouble falling asleep or staying asleep, or sleeping too much</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>4. Feeling tired or having little energy</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>5. Poor appetite or overeating</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>6. Feeling bad about yourself-or that you are a failure or have let yourself or your family down</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>7. Trouble concentrating on things such as reading the newspaper or watching television</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>8. Moving or speaking so slowly that other people have noticed. Or the opposite-being so fidgety or restless that you have been moving around a lot more than usual</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Thoughts that you would be better off dead or of hurting yourself in some way</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

**SUM OF ALL COLUMNS=**

10. If you have had any of these problems, how difficult have they made it for you to do your work, take care of things at home, or get along with other people? (circle the best answer)

<table>
<thead>
<tr>
<th>Not difficult at all</th>
<th>Somewhat difficult</th>
<th>Very difficult</th>
<th>Extremely difficult</th>
</tr>
</thead>
</table>

Patient Health Questionnaire-9 (PHQ-9). The PHQ was developed by Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke, and colleagues. For research information, contact Dr. Spitzer at

---

**Initial Approval Date and Reviews:**
April 2013, April 2015, April 2017

**Most Recent Revision and Approval Date:**
April 2017

**Next Scheduled Review Date:**
April 2019 Ambulatory Best Practice

© Copyright MedStar Health, 2012
Scoring PHQ-9: Confirmation of Depression and Patient Monitoring

A. Scoring instructions: The total PHQ-9 score is the sum of the scores for the responses to questions 1 through 9.
B. If there are at least 4 checks in the gray highlighted section (including Questions #1 and #2), consider a depressive disorder. Add score to determine severity.

<table>
<thead>
<tr>
<th>Interpretation of Total Score</th>
<th>Total Score Depression Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1-4 Minimal depression</td>
</tr>
<tr>
<td></td>
<td>5-9 Mild depression</td>
</tr>
<tr>
<td></td>
<td>10-14 Moderate depression</td>
</tr>
<tr>
<td></td>
<td>15-19 Moderately severe depression</td>
</tr>
<tr>
<td></td>
<td>20-27 Severe depression</td>
</tr>
</tbody>
</table>

C. Consider Major Depressive Disorder
If there are at least 5 checks in the gray highlighted section (one of which corresponds to Question #1 or #2)

D. Consider Other Depressive Disorder
If there are 2 to 4 checks in the gray highlighted section (one of which corresponds to Question #1 or #2)

Note: Since the questionnaire relies on patient self-report, all responses should be verified by the clinician and a definitive diagnosis made on clinical grounds, taking into account how well the patient understood the questionnaire, as well as other relevant information from the patient. Diagnoses of Major Depressive Disorder or Other Depressive Disorder also require impairment of social, occupational, or other important areas of functioning (Question #10) and ruling out normal bereavement, a history of a Manic Episode (Bipolar Disorder), and a physical disorder, medication, or other drug as the biological cause of the depressive symptoms.

© Copyright MedStar Health, 2012
E. To monitor severity over time for newly diagnosed patients or patients in current treatment for depression:

<table>
<thead>
<tr>
<th>Initial response after Four weeks of an Adequate Dose of an Antidepressant</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PHQ 9</strong></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Drop of 5 points from baseline</td>
</tr>
<tr>
<td>Drop of 2-4 points from baseline</td>
</tr>
<tr>
<td>Drop of 1 point or no change or increase</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Initial response after Six weeks of Psychological Counseling</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PHQ 9</strong></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Drop of 5 points from baseline</td>
</tr>
<tr>
<td>Drop of 2-4 points from baseline</td>
</tr>
<tr>
<td>Drop of 1 point or no change or increase</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Adapted from MacArthur Depression Toolkit  www.depression-primarycare.org